| Name | Description | Data sources | Responsible organisation(s) | Measure methodology last updated |
|---|---|---|---|---|
| People with diabetes regularly receiving any hypoglycaemic medication in the relevant year | This indicator shows the number and percent of people with diabetes receiving any hypoglycaemic medication regularly. Regular use was defined as hypoglycaemic medication dispensed in three or more quarters in a year |
Pharmaceutical Collection (PHARMS), Primary Health Organisation (PHO) Enrolment Collection, Virtual Diabetes Register (VDR) | Health Quality & Safety Commission | Te Tāhū Hauora | June 2024 |
| People with diabetes regularly receiving sulfonylureas | This indicator shows the number and percent of people with diabetes receiving sulfonylureas (glibenclamide, gliclazide and glipizide) regularly. Regular use was defined as sulfonylureas dispensed in three or more quarters in a year. |
Pharmaceutical Collection (PHARMS), Primary Health Organisation (PHO) Enrolment Collection, Virtual Diabetes Register (VDR) | Health Quality & Safety Commission | Te Tāhū Hauora | June 2024 |
| People with diabetes regularly receiving dulaglutide | This indicator shows the number and percent of people with diabetes receiving dulaglutide regularly. Regular use was defined as dulaglutide dispensed in three or more quarters in a year. |
Pharmaceutical Collection (PHARMS), Primary Health Organisation (PHO) Enrolment Collection, Virtual Diabetes Register (VDR) | Health Quality & Safety Commission | Te Tāhū Hauora | June 2024 |
| People with diabetes regularly receiving empagliflozin | This indicator shows the number and percent of people with diabetes receiving empagliflozin regularly. Regular use was defined as empagliflozin dispensed in three or more quarters in a year. |
Pharmaceutical Collection (PHARMS), Primary Health Organisation (PHO) Enrolment Collection, Virtual Diabetes Register (VDR) | Health Quality & Safety Commission | Te Tāhū Hauora | June 2024 |
| People with diabetes regularly receiving vildagliptin | This indicator shows the number and percent of people with diabetes receiving vildagliptin regularly. Regular use was defined as vildagliptin dispensed in three or more quarters in a year. |
Pharmaceutical Collection (PHARMS), Virtual Diabetes Register (VDR) | Health Quality & Safety Commission | Te Tāhū Hauora | June 2024 |
| People aged 12–44 dispensed a combined budesonide + formoterol inhaler | This indicator shows the number and percent of people aged 12-44 years who were regularly dispensed SMART Formoterol/Budesonide therapy. Regular dispensing was defined as dispensing in two or more quarters in the year. This indicator measures uptake of this inhaler, relative to other asthma inhalers. Specifically, of all people who were dispensed any asthma inhaler (SABA, LABA, ICS or LABA/ICS combination), what percentage were dispensed a combined budesonide + formoterol inhaler. |
Pharmaceutical Collection (PHARMS), PHO Enrolment Collection | Health Quality & Safety Commission | Te Tāhū Hauora | September 2025 |
| Dispensed a urate-lowering therapy | This measure shows the percentage of people with identified gout who received urate-lowering therapy at least once in a year. Long-term urate-lowering therapy is used to prevent gout flares and prevent tophus formation, bony erosions and permanent disability in people with gout. Many studies have demonstrated underutilisation of urate-lowering therapy continuously and long term. | National Minimum Dataset, Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ | Health Quality & Safety Commission | Te Tāhū Hauora | |
| Residents dispensed vitamin D in aged residential care (ARC) | Percentage of ARC residents who were dispensed vitamin D. Internationally, vitamin D is widely recommended for reducing falls and fall-related injuries in older people. Vitamin D supplements are thought to prevent falls by improving muscle strength and psychomotor performance in older people at risk of vitamin D deficiency. Nationally, there has been a long-established programme to increase the uptake of prescribed vitamin D supplements to older people in ARC. | Pharmaceutical Collection (PHARMS), Client claims processing system – Manatū Hauora | Health Quality & Safety Commission | Te Tāhū Hauora | |
| Bisphosphonates new starts | This is a measure of people newly started on bisphosphonates as a proportion of ACC fracture claims. Bisphosphonates are a class of drugs that reduce bone density loss. Bisphosphonates should be considered for people who have fallen and sustained a fracture, to reduce their future risk of fracture. ‘New starts’ identifies people who were not covered by bisphosphonates in the previous 2 years. | Pharmaceutical Collection (PHARMS), Claims data – ACC | Health Quality & Safety Commission | Te Tāhū Hauora | |
| Bisphosphonates coverage | This is a measure of the percentage of people in the population covered by bisphosphonates. Bisphosphonates are a class of drugs that reduce bone density loss. Bisphosphonates should be considered for people who have fallen and sustained a fracture to reduce their future risk of fracture. | Pharmaceutical Collection (PHARMS), National Population Projection - Stats NZ | Health Quality & Safety Commission | Te Tāhū Hauora |